Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1995 Dec 16;311(7020):1602–1607. doi: 10.1136/bmj.311.7020.1602

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.

A J Lees 1
PMCID: PMC2551499  PMID: 8555803

Abstract

OBJECTIVE: To compare effectiveness of levodopa and levodopa combined with selegiline in treating early, mild Parkinson's disease. DESIGN: Open, long term, prospective randomised trial. SETTING: 93 hospitals throughout United Kingdom. SUBJECTS: 520 patients with early Parkinson's disease who were not receiving dopaminergic treatment. INTERVENTIONS: Treatment with levodopa and dopa decarboxylase inhibitor (arm 1) or levodopa and decarboxylase inhibitor in combination with selegiline (arm 2). MAIN OUTCOME MEASURES: Assessments of serial disability, frequency and severity of adverse events, and deaths from all causes. RESULTS: After average of 5-6 years' follow up, mortality ratio in arm 2 compared with arm 1 was 1.57 (95% confidence interval 1.09 to 2.30), and difference in survival between the two arms was significant (log rank test, P = 0.015). Hazard ratio adjusted for age and sex was 1.49 (1.02 to 2.16), and after adjustment for other baseline factors it increased to 1.57 (1.07 to 2.31). Patients in arm 1 had slightly worse disability scores than those in arm 2, but differences were not significant. Functionally disabling peak dose dyskinesias and on/off fluctuations were more frequent in arm 2 than arm 1. During the trial the dose of levodopa required to produce optimum motor control steadily increased in arm 1 (median daily dose 375 mg at 1 year and 625 mg at 4 years), but median dose in arm 2 did not change (375 mg). CONCLUSIONS: Levodopa in combination with selegiline seemed to confer no clinical benefit over levodopa alone in treating early, mild Parkinson's disease. Moreover mortality was significantly higher with combination treatment, casting doubts on its chronic use in Parkinson's disease.

Full text

PDF
1602

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brannan T., Yahr M. D. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol. 1995 Jan;37(1):95–98. doi: 10.1002/ana.410370117. [DOI] [PubMed] [Google Scholar]
  2. CANTER G. J., DE LA TORRE R., MIER M. A method for evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis. 1961 Aug;133:143–147. doi: 10.1097/00005053-196108000-00010. [DOI] [PubMed] [Google Scholar]
  3. Clarke C. E. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord. 1995 May;10(3):250–256. doi: 10.1002/mds.870100303. [DOI] [PubMed] [Google Scholar]
  4. Cohen G., Spina M. B. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol. 1989 Nov;26(5):689–690. doi: 10.1002/ana.410260518. [DOI] [PubMed] [Google Scholar]
  5. Gibb W. R., Lees A. J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745–752. doi: 10.1136/jnnp.51.6.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  7. Marsden C. D., Parkes J. D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1976 Feb 7;1(7954):292–296. doi: 10.1016/s0140-6736(76)91416-1. [DOI] [PubMed] [Google Scholar]
  8. Poewe W. H., Lees A. J., Stern G. M. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology. 1986 Nov;36(11):1528–1530. doi: 10.1212/wnl.36.11.1528. [DOI] [PubMed] [Google Scholar]
  9. Shaw K. M., Lees A. J., Stern G. M. The impact of treatment with levodopa on Parkinson's disease. Q J Med. 1980;49(195):283–293. [PubMed] [Google Scholar]
  10. Tatton W. G., Greenwood C. E. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res. 1991 Dec;30(4):666–672. doi: 10.1002/jnr.490300410. [DOI] [PubMed] [Google Scholar]
  11. Ward C. D. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry. 1994 Feb;57(2):217–220. doi: 10.1136/jnnp.57.2.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Webster D. D. Critical analysis of the disability in Parkinson's disease. Mod Treat. 1968 Mar;5(2):257–282. [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES